Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Nutriband ( (NTRB) ) is now available.
On February 7, 2025, Nutriband Inc. announced it received a Notice of Allowance from the USPTO for its patent application covering the Aversa™ abuse deterrent technology. This development is anticipated to enhance Nutriband’s intellectual property protection in the U.S. for its transdermal systems designed to deter drug abuse and misuse. The AVERSA™ technology, protected by an extensive international patent portfolio, is aimed at preventing the abuse and accidental exposure of drugs, with the potential for significant market impact, particularly through its Aversa™ Fentanyl patch.
More about Nutriband
Nutriband Inc. is primarily engaged in the development of transdermal pharmaceutical products, focusing on creating solutions that deter abuse and misuse. The company’s lead product under development is an abuse-deterrent fentanyl patch using its proprietary AVERSA™ technology, which can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
YTD Price Performance: 52.31%
Average Trading Volume: 195,445
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $79.41M
For an in-depth examination of NTRB stock, go to TipRanks’ Stock Analysis page.
